- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00405418
Lantus Versus Levemir Treat-To-Target (L2T3)
Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.
Primary objective:
To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56 mg/dL (3.1 mmol/L)
Secondary objectives:
- To compare between the 2 treatment groups, the percentage of patients who reach the target of HbA1c < 7% and < 6.5% at the end of the treatment period
- To compare the changes in HbA1c and fasting plasma glucose (FPG)
- To compare the evolution of blood glucose profiles
- To compare the day to day FPG variability, the insulin doses
- To determine in each treatment group the biochemical and patient-related determinants of failure to reach HbA1c targets
- To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L)
- To compare over the treatment period, the overall incidence and rate of symptomatic hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL [3.9 mmol/L]), of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL
- To compare the overall safety: incidence of adverse events (including serious hypoglycemia and local tolerance at injection site), change in body weight, in waist circumference and in waist / hip ratio
- To assess the quality of life and treatment satisfaction
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
North Ryde, Australia
- Sanofi-Aventis
-
-
-
-
-
Sao Paolo, Brazil
- Sanofi-Aventis
-
-
-
-
-
Laval, Canada
- Sanofi-Aventis
-
-
-
-
-
Hoersholm, Denmark
- Sanofi-Aventis
-
-
-
-
-
Helsinki, Finland
- Sanofi-Aventis
-
-
-
-
-
Berlin, Germany
- Sanofi-Aventis
-
-
-
-
-
Mumbai, India
- Sanofi-Aventis
-
-
-
-
-
Dublin, Ireland
- Sanofi-Aventis
-
-
-
-
-
Seoul, Korea, Republic of
- Sanofi-Aventis
-
-
-
-
-
Gouda, Netherlands
- Sanofi-Aventis
-
-
-
-
-
Porto Salvo, Portugal
- Sanofi-Aventis
-
-
-
-
-
Bucharest, Romania
- Sanofi-Aventis
-
-
-
-
-
Moscow, Russian Federation
- Sanofi-Aventis
-
-
-
-
-
Belgrade, Serbia
- Sanofi-Aventis
-
-
-
-
-
Barcelona, Spain
- Sanofi-Aventis
-
-
-
-
-
Stockholm, Sweden
- Sanofi-Aventis
-
-
-
-
-
Meyrin, Switzerland
- Sanofi-Aventis
-
-
-
-
-
Taipe, Taiwan
- Sanofi-Aventis
-
-
-
-
-
Istanbul, Turkey
- Sanofi-Aventis
-
-
-
-
-
Guildford, United Kingdom
- Sanofi-Aventis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes for at least 1 year
- Insulin naïve
- Treated with stable doses of oral antidiabetics for at least 3 months prior to study start, including at least metformin (at least 1g/day)
- 7% ≤ HbA1c ≤ 10.5 %
- Body mass index (BMI) < 40 kg/m²
- Ability and willingness to perform blood glucose monitoring using a blood glucose meter and to use a patient diary
Exclusion Criteria:
- Type 1 diabetes
- Current or previous use of insulin (except for previous treatment of gestational diabetes or brief treatment with insulin for less than 1 week)
- Treatment with glucagon-like peptide (GLP)-1 receptor agonists or with dipeptidyl peptidase (DPP)-IV inhibitors
- Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)
- Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method)
- Breast-feeding
- History of hypersensitivity to the study drugs or to drugs with a similar chemical structure
- Treatment with systemic corticosteroids in the 3 months prior to study entry
- Treatment with any investigational product in the 2 months prior to study entry
- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
- Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
- Impaired hepatic function as shown by Alamine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal range at study entry
- Impaired renal function as shown by serum creatinine ≥ 1.5 mg/dL (≥ 133 μmol/L) in men and ≥ 1.4 mg/dL (124 μmol/L) in women at study entry
- History of drug or alcohol abuse in the last year
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1
Insulin Glargine
|
Subcutaneous injection, once a day in the evening
|
|
Active Comparator: 2
Insulin Detemir
|
Subcutaneous injection, twice a day at breakfast and before dinner
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
HbA1c recorded
Time Frame: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
|
Self-monitored fasting BG in both treatment arms and pre-dinner BG in detemir arm
Time Frame: On the 4 consecutive days before each visit
|
On the 4 consecutive days before each visit
|
|
Self-monitored BG values from 8-point 24-hour profile recorded on 2 consecutive days
Time Frame: Within the week prior to baseline, week 12 and week 24
|
Within the week prior to baseline, week 12 and week 24
|
|
Episodes of hypoglycemia (symptomatic, total and categorized as day-time/nocturnal, severe or asymptomatic)
Time Frame: All across the study
|
All across the study
|
|
Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.
Time Frame: All across the study
|
All across the study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Doses of insulin glargine or insulin detemir
Time Frame: Daily
|
Daily
|
|
Laboratory fasting plasma glucose
Time Frame: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
|
Insulinemia and fasting C-peptide level
Time Frame: At baseline
|
At baseline
|
|
Lipid profile
Time Frame: at baseline and week 24
|
at baseline and week 24
|
|
Patient reported outcomes (quality of life and treatment satisfaction)
Time Frame: at baseline, week 4, week 12 and at the last visit
|
at baseline, week 4, week 12 and at the last visit
|
|
Safety data: occurrence of adverse events and weight
Time Frame: assessed at each visit
|
assessed at each visit
|
|
Waist and hip circumferences
Time Frame: measured at baseline, week 12 and week 24
|
measured at baseline, week 12 and week 24
|
|
Systolic and diastolic blood pressure
Time Frame: measured at study entry, baseline, week 12 and week 24
|
measured at study entry, baseline, week 12 and week 24
|
|
Physical examination
Time Frame: performed at study entry and at last visit.
|
performed at study entry and at last visit.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Valérie Pilorget, Sanofi
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LANTU_C_00579
- EUDRACT # : 2006-000324-13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.